Dual-function polypeptide having effects of reducing blood sugar and regulating immunity and use of dual-function polypeptide
An immunomodulatory and hypoglycemic polypeptide technology, applied in the field of biochemical pharmacy, can solve the problem of inability to promote the proliferation of pancreatic β cells, and achieve the effects of inhibiting immune attack, inhibiting eating, and reducing glycosylated hemoglobin
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0112] Embodiment 1: the drug efficacy comparison of polypeptide Progly-VP of the present invention and Progly peptide, VP peptide
[0113] (1) The fusion of hypoglycemic peptides and immunomodulatory peptides has directionality
[0114] Eight-week-old male C57BL / 6 mice were randomly divided into 3 groups, 10 mice in each group, which were solvent control group (negative control Vehicle group), Progly-VP group, and VP-Progly group for glucose tolerance test. The result is as figure 1 As shown in A, compared with the control group, the Progly-VP group can significantly reduce the blood glucose level. figure 1 B shows that the area under the curve of the Progly-VP group is also significantly lower than that of the control group, and when VP-Progly is linked in this way, the drug effect is reduced, indicating that the fusion of the hypoglycemic peptide and the immunomodulatory peptide has directionality.
[0115] (2) The dual functions of hypoglycemic and immune regulation depe...
Embodiment 2
[0154] Example 2: Comparison of the efficacy of polypeptide P8-VP of the present invention with P8 peptide and VP peptide
[0155] (1) The fusion of hypoglycemic peptides and immunomodulatory peptides has directionality
[0156] Eight-week-old male C57BL / 6 mice were randomly divided into 3 groups, 10 mice in each group, which were solvent control group (negative control Vehicle group), P8-VP group, and VP-P8 group for glucose tolerance test. The result is as Figure 13 As shown in A, compared with the control group, the P8-VP group can significantly reduce the blood glucose level. Figure 13 B shows that the area under the curve of the P8-VP group is also significantly lower than that of the control group, and when VP-P8 is linked in this way, the drug effect is reduced, indicating that the fusion of the hypoglycemic peptide and the immunomodulatory peptide has directionality.
[0157] (2) The dual functions of hypoglycemic and immune regulation depend on the fusion of these...
Embodiment 3
[0196] Example 3: Comparison of the efficacy of polypeptide Progly-P20 of the present invention with Progly peptide and P20 peptide
[0197] (1) The fusion of hypoglycemic peptides and immunomodulatory peptides has directionality
[0198] Eight-week-old male C57BL / 6 mice were randomly divided into 3 groups, 10 mice in each group, which were solvent control group (negative control Vehicle group), Progly-P20 group, and P20-Progly group for glucose tolerance test. The result is as Figure 25 As shown in A, compared with the control group, the Progly-P20 group can significantly reduce the blood glucose level. Figure 25 B shows that the area under the curve of the Progly-P20 group is also significantly lower than that of the control group, and when the P20-Progly is linked in this way, the drug effect is reduced, indicating that the fusion of the hypoglycemic peptide and the immunomodulatory peptide has directionality.
[0199] (2) The dual functions of hypoglycemic and immune r...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com